2. December 2022
© 2021 Adrenomed AG | Imprint/Impressum | Legal Notice/Datenschutzerklärung
2022
Adrenomed to attend upcoming industry and investor conferences
Hennigsdorf/Berlin (Germany), October 13, 2022 – Adrenomed AG, the vascular integrity company, today announced its participation in upcoming industry and investor conferences. The Adrenomed management team will be available for meetings to present and discuss
13. October 2022
Adrenomed appoints David Germonpré as Chief Financial Officer
Hennigsdorf/Berlin (Germany), July 12, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of David Germonpré as Chief Financial Officer (CFO) of Adrenomed, effective July 11, 2022. David Germonpré has over 15
12. July 2022
Article in GoingPublic’s Plattform Life Sciences: “A phenomenal breakthrough is taking shape”
“A phenomenal breakthrough is taking shape” An interview with Dr. Rainer Strohmenger, Managing Partner at Wellington Partners (Original interview in German)
4. July 2022
Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer
Hennigsdorf/Berlin (Germany), June 23, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. med. Steffen Stürzebecher as Chief Medical Officer (CMO) of Adrenomed, effective June 20, 2022. Dr. Stürzebecher is
23. June 2022
Article in Pink Sheet’s Coronavirus Notebook: UK Adds Paxlovid To PANORAMIC Study, Germany Funds Adrecizumab Phase II Trial
by Ian Schofield Executive Summary RedHill’s opaganib has shown “potent inhibition” of the Omicron variant in early studies, while the EMA has found nolinks between the mRNA vaccines and autoimmune hepatitis. Read the full
12. April 2022
PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients
Adrecizumab selected to receive funding from two COVID-19 drug development programs of the German Federal Ministry of Education and Research (BMBF) By restoring vascular integrity, Adrecizumab addresses the endothelial barrier dysfunction as a consequence of
11. April 2022
Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO
Hennigsdorf/Berlin (Germany), 15 March, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. Richard Jones as Chief Executive Officer of Adrenomed, effective today. Dr. Jones brings over 25 years of
15. March 2022
March conference update: 41st ISICEM and BIO-Europe Spring 2022
In March, Adrenomed will be attending the 41st International Symposium on Intensive Care & Emergency Medicine, Brussels, Belgium. Conference dates: 22 – 25 March 2022 Additionally, Adrenomed will participate in BIO-Europe Spring (digital) Conference dates:
7. March 2022